A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report

World J Surg Oncol. 2014 Mar 26:12:63. doi: 10.1186/1477-7819-12-63.

Abstract

Background: Pathological complete remission of advanced stage rectal adenocarcinoma by chemotherapy alone is rare. A case of advanced stage, low-lying rectal adenocarcinoma in which a complete response to treatment was obtained with mFOLFOX6 and panitumumab (Pmab) is reported.

Case presentation: A 53-year-old man was referred to Shiga University of Medical Science hospital Shiga, Japan, complaining of bloody stool. Gastrointestinal endoscopy was performed, and advanced stage rectal adenocarcinoma was diagnosed. Computed tomography (CT) revealed regional lymph node metastases in the mesorectum. Neoadjuvant chemotherapy (NAC) with mFOLFOX6 and Pmab was planned.Endoscopy following four courses of chemotherapy revealed that the rectal cancer had been markedly reduced, and the results of biopsies of the rectal tumor were negative for cancer. On CT, the mesorectal lymph node metastases had disappeared. Total intersphincteric resection (ISR) with a handsewn coloanal anastomosis was performed. Histological examination showed a complete response to mFOLFOX6 and Pmab in advanced stage rectal cancer.

Conclusion: The result seen in this case suggests that short-term NAC with mFOLFOX6 and Pmab was effective for low-lying rectal adenocarcinoma.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary
  • Antibodies, Monoclonal / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Fluorouracil / administration & dosage
  • Humans
  • Leucovorin / administration & dosage
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Organoplatinum Compounds / administration & dosage
  • Panitumumab
  • Prognosis
  • Rectal Neoplasms / drug therapy*
  • Rectal Neoplasms / pathology
  • Remission Induction

Substances

  • Antibodies, Monoclonal
  • Organoplatinum Compounds
  • Panitumumab
  • Leucovorin
  • Fluorouracil